Feasibility of simultaneous integrated boost for high-dose treatment of high-risk prostate cancer
نویسندگان
چکیده
Background . Radiation therapy for high-risk prostate cancer presents a challenge radiotherapists. The improvement of treatment outcomes is associated with radiation dose escalation and prophylactic irradiation lymph nodes, therefore, the development new schemes needed. Simultaneous integrated boost technique based on volumetric modulated arc most efficient option. Material Methods anatomical data 10 patients was used dosimetry-based planning. Both simultaneous sequential were considered. planning goal to deliver equivalent 96 Gy at 2 per fraction ( EQD =96 Gy) (α/β=1.5 prostate, =62.5 seminal vesicles =50 nodes avoiding damaging organs risk, mainly bladder rectum. two partially coplanar arcs rotations each arc. obtained distributions compared respect dose-volume histograms uniform doses (EUD). Results In case boost, minimal delivered equal 95.9 ± 2.1 Gy, EUD=104.9 1.7 Gy. cm 3 D 2cc ) 97.4 2.0 Normal tissue complication probability (NTCP) 1.64 %. cm3 rectum 103.4 9.2 NTCP 27.4 90.4 2.3 EUD =103.9 1.3 as high =96.1 5.2 =0.176 0.132 %, - =81.1 6.0 =2.34 1.92 Conclusion Volumetric along have shown feasibility up prescribed values without significant over risk (OARs). Dose in tumor may result higher control value should be considered clinical trials.
منابع مشابه
Effectiveness of High Dose Pralidoxime for Treatment of Organophosphate Poisoning
Background: For effective treatment of organophosphate (OP) poisoning, development of a standardized protocol with flexible dose regimen for atropine and pralidoxime is an essential step. In this study, we aimed to assess the protocol devised in our setting; Bach Mai Hospital Poison Treatment Center, for treatment of OP poisoning that included a higher dose regimen of pralidoxime (2PAM). Method...
متن کاملObstructive urination problems after high-dose-rate brachytherapy boost treatment for prostate cancer are avoidable
BACKGROUND Aiming at improving treatment individualization in patients with prostate cancer treated with combination of external beam radiotherapy and high-dose-rate brachytherapy to boost the dose to prostate (HDRB-B), the objective was to evaluate factors that have potential impact on obstructive urination problems (OUP) after HDRB-B. PATIENTS AND METHODS In the follow-up study 88 patients ...
متن کاملBrachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer.
PURPOSE Recent retrospective data suggest that brachytherapy (BT) boost may confer a cancer-specific survival benefit in radiation-managed high-risk prostate cancer. We sought to determine whether this survival benefit would extend to the recently defined favorable high-risk subgroup of prostate cancer patients (T1c, Gleason 4 + 4 = 8, PSA < 10 ng/ml or T1c, Gleason 6, PSA > 20 ng/ml). MATERI...
متن کاملPercutaneous prostate cryoablation as treatment for high-risk prostate cancer.
PURPOSE To evaluate percutaneous cryotherapy as a primary treatment option for high-risk prostate cancer patients. PATIENTS AND METHODS From October 2000 to February 2005, 21 high-risk (Gleason e.8 and/or PSA > 10 and/or stage > T2a) prostate cancer patients underwent 24 percutaneous prostate cryoablation procedures. Patients' median age was 70.9, and the average pretreatment PSA was 19.5 ng/...
متن کاملSimultaneous integrated boost radiotherapy for thyroid cancer.
AIM The purpose of this study was to examine the usefulness of using Simultaneous Integrated Boost (SIB) radiotherapy for thyroid cancer treatment. BACKGROUND At our hospital a 3D Conformal RadioTherapy (3D-CRT) technique involving photon and electron beams for the treatment of thyroid cancer was often used.(1) High dose to the spinal canal was limiting the total dose of such a treatment. Aft...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: ????????? ?????????????? ??????
سال: 2023
ISSN: ['1813-7083']
DOI: https://doi.org/10.21294/1814-4861-2023-22-3-57-65